Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

1.2. Definitions Ulcerative colitis [UC] is a chronic inflammatory condition that causes
continuous mucosal inflammation of the colon, usually without granulomas on biopsy. It …

Background & Aims Infliximab, a tumor necrosis factor antagonist, is effective for treating
patients with Crohn's disease (CD) and ulcerative colitis (UC). We aimed to determine …

When deciding the appropriate treatment strategy for active ulcerative colitis one should
consider the activity, distribution (proctitis, left-sided, extensive 1), and pattern of disease …

Background Therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD)
patients receiving anti‐tumour necrosis factor (TNF) agents can help optimise outcomes …

Background & Aims It is not clear why some patients with ulcerative colitis (UC) do not
respond to treatment with anti-tumor necrosis factor (TNF) agents, such as infliximab. It could …

The management of inflammatory bowel disease represents a key component of clinical
practice for members of the British Society of Gastroenterology (BSG). There has been …

Background Nonresponse and loss of response to anti‐TNF therapies in Crohn's disease
represent significant clinical problems for which clear management guidelines are lacking …

The goal of this consensus initiated by the European Crohn's and Colitis Organisation
(ECCO) was to establish European consensus guidelines for the surgical treatment of …

Background Failure of anti-TNF treatment in inflammatory bowel disease (IBD) patients can
take on several forms, each posing distinct etio-pathogenic considerations and management …